title: The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
abstract: Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment.
  
  
  
  We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014.
  
  
  
  Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P = .7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P = .399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone ( P > .05).
  
  
  
  Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Hsiu-Ying
authors.initials: HY
authors.lastname: Hung
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.|2 National Yang-Ming University, Taipei, Taiwan, Republic of China.
authors.forename: Yen-Han
authors.initials: YH
authors.lastname: Tseng
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Chia-Miao
authors.initials: CM
authors.lastname: Liao
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Sung-Yi
authors.initials: SY
authors.lastname: Chen
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Ta-Peng
authors.initials: TP
authors.lastname: Wu
authors.affiliation: 3 Sijhih Cathay General Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Yu-Chin
authors.initials: YC
authors.lastname: Lee
authors.affiliation: 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.|2 National Yang-Ming University, Taipei, Taiwan, Republic of China.|4 Taipei Medical University, Taipei, Taiwan, Republic of China.
authors.forename: Yuh-Min
authors.initials: YM
authors.lastname: Chen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D004365:Drugs, Chinese Herbal; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
keywords: Chinese herbal medicine; adenocarcinoma; epidermal growth factor receptor; lung cancer; tyrosine kinase inhibitor